Pallas Capital Advisors LLC Buys 76 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Pallas Capital Advisors LLC lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 11,752 shares of the medical research company’s stock after buying an additional 76 shares during the quarter. Pallas Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $7,269,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in TMO. Claro Advisors LLC purchased a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $345,000. Oak Thistle LLC bought a new position in Thermo Fisher Scientific in the first quarter valued at about $321,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Thermo Fisher Scientific by 40.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 125,565 shares of the medical research company’s stock worth $72,980,000 after purchasing an additional 36,169 shares during the period. MV Capital Management Inc. increased its holdings in Thermo Fisher Scientific by 13.1% during the first quarter. MV Capital Management Inc. now owns 199 shares of the medical research company’s stock valued at $116,000 after buying an additional 23 shares during the last quarter. Finally, SeaCrest Wealth Management LLC grew its position in shares of Thermo Fisher Scientific by 2.5% during the 1st quarter. SeaCrest Wealth Management LLC now owns 1,654 shares of the medical research company’s stock valued at $961,000 after acquiring an additional 40 shares during the period. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.34% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Stephens began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, October 1st. They set an “overweight” rating and a $680.00 target price on the stock. Bernstein Bank increased their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a report on Tuesday, October 22nd. TD Cowen upped their target price on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Redburn Atlantic initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a “buy” rating and a $680.00 price target on the stock. Finally, Barclays dropped their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $649.33.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $552.68 on Tuesday. The company’s 50 day moving average is $604.03 and its 200 day moving average is $583.92. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The firm has a market cap of $211.12 billion, a price-to-earnings ratio of 34.65, a PEG ratio of 3.66 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52-week low of $420.21 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter last year, the company earned $5.69 earnings per share. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.